Coherus BioSciences, Inc. (NASDAQ:CHRS) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Coherus BioSciences, Inc. (NASDAQ:CHRS) has earned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a hold recommendation and three have given a buy recommendation to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $7.13.

A number of research analysts have recently commented on CHRS shares. StockNews.com downgraded shares of Coherus BioSciences from a “buy” rating to a “hold” rating in a research report on Saturday, October 19th. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Coherus BioSciences in a report on Monday, September 16th. Finally, UBS Group downgraded Coherus BioSciences from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $4.00 to $1.50 in a research report on Friday, August 16th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of CHRS. Nisa Investment Advisors LLC boosted its holdings in shares of Coherus BioSciences by 2,672.8% during the second quarter. Nisa Investment Advisors LLC now owns 20,657 shares of the biotechnology company’s stock worth $36,000 after acquiring an additional 19,912 shares during the period. TIAA Trust National Association acquired a new stake in Coherus BioSciences during the 2nd quarter worth approximately $47,000. Bayesian Capital Management LP bought a new stake in Coherus BioSciences in the 1st quarter valued at $56,000. Price T Rowe Associates Inc. MD grew its holdings in Coherus BioSciences by 32.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 30,851 shares of the biotechnology company’s stock valued at $74,000 after buying an additional 7,608 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Coherus BioSciences during the 1st quarter worth $94,000. Institutional investors and hedge funds own 72.82% of the company’s stock.

Coherus BioSciences Trading Down 3.0 %

CHRS opened at $0.72 on Monday. The business’s 50-day simple moving average is $1.06 and its 200 day simple moving average is $1.50. Coherus BioSciences has a 52-week low of $0.71 and a 52-week high of $3.73.

Coherus BioSciences (NASDAQ:CHRS) last announced its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.10. The company had revenue of $64.98 million for the quarter, compared to the consensus estimate of $57.08 million. As a group, research analysts predict that Coherus BioSciences will post -1.16 earnings per share for the current year.

About Coherus BioSciences

Coherus BioSciences, Inc, a biopharmaceutical company, focuses on the research, development, and commercialization of cancer treatments primarily in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel PD-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype G1 (IgG1) monoclonal antibody targeting interleukin 27.